盐酸埃克替尼一线治疗晚期肺腺癌的临床疗效观察
万方数据
万方数据
万方数据
万方数据
万方数据
盐酸埃克替尼一线治疗晚期肺腺癌的临床疗效观察
作者：杨新杰， 张卉， 秦娜， 李曦， 农靖颖， 吕嘉林， 吴羽华， 张权， 张树才
作者单位：首都医科大学附属北京胸科医院/北京市结核病胸部肿瘤研究所肿瘤内科,北京,101149
刊名：
中国肺癌杂志
英文刊名：Chinese Journal of Lung Cancer
年，卷(期)：2013,16(7)
参考文献(17条)
1.FerlayJ;Autier P;Boniol M Estimates of the cancer incidence and mortality in Europe in 2006[外文期刊] 2007(03)
2.Edward HL The cancef-Mmatrix Munaal.5th ed 2010
3.Anonymous Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer:a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials 2008(28)
4.Mok TS;Wu YL;Thongpraser t S Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma 2009(10)
5.Mitsudomi T;Morita S;Yatabe Y Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405):an open label,randomized phase 3 trial
2010(02)
6.Maemondo M;Inoue A;Kobayashi K Gefitinib or chemo-therapy for non-small-cell lung cancer with mutated EGFR 2010(25)
7.Kim ES;Hirsh V;Mok T Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST):a randomized phase Ⅲ trial 2008(9652)
8.Zhou CC;Wu YL;Chen GY Erlotinib versus chemotherapy as firstline treatment for patients with advanced EGFR
mutation-positive nonsmall-cell lung cancer (OPTIMAL,CTONG-0802):a multicenter,openlabel,randomized,phase 3 study 2011(08)
9.谭芬来;张力;赵琼盐酸埃克替尼的药理与临床评价 2009(18)
10.Liu DY;JiangJ;Hu P Quantitative determination oficotinib in human plasma and urine using liquid chromatography coupled to tandem mass spectrometry 2009(30)
11.Ren GJ;Zhao YY;Zhang L Tumor gene mutations and messenger RNA expression to icotinib hydrochloride in non-small-cell lung cancer[期刊论文]-Chinese Medical Journal(Engl) 2011(01)
12.Zhao Q;ShentuJ;Xu N Phase Ⅰ study oficotinib hydrochloride (BPI-2009H),an oral EGFR tyrosine kinase inhibitor,in patients with advanced NSCLC and other solid tumors 2011(02)
13.Sun Y;Shi Y;Zhang L A randomized,double-blind phase Ⅲ study oficotinib versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (ICOGEN)(Abstract 7522) 2011(Suppl)
14.李曦;杨新杰;孙怡芬盐酸埃克替尼治疗晚期非小细胞肺癌的临床观察[期刊论文]-中华肿瘤杂志 2012(08)
15.Pan-Chyr Y;Yuankai S;Joseph SA Molecular epidemiological prospective study of EGFR mutation form Asia
patients(pts) with advanced lung adenocarcinoma (PIONEER)(Abstr 1534) 2012(Suppl)
16.Jackman DM;Miller VA;Cioffredi LA Impact of epidermal growth factor receptor receptor and KRAS mutations on
clinical outcomes in previously untreated non-small cell lung cancer patients:results of an online tumor registry of clinical trials[外文期刊] 2009(16)
17.Morita S;Okamoto I;Kobayashi K Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations[外文期刊] 2009(13)
本文链接：https://www.wendangku.net/doc/ee6554342.html,/Periodical_zgfazz201307006.aspx